$SGEN may be forming the “cup” of a cup and handle formation. I would look to see if it corrects its advance soon to develop the handle.
Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS): AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and...
As indicated on the chart, SGEN entered oversold territory at the end of October which was immediately followed by a Bullish RSI divergence. We can see that price just bounced at support line that has been holding strong since May and at the same time we received a bull signal from our MACD. SGEN is down over 40% since May and considering the strong bullish...
Buying here with a stop on any close below the 252 day moving average. I am looking for price to head back to the 195 area. SGEN has burned me recently but I am taking another shot at range lows. I like the rate of change divergence.
Double bottom has formed... Look for strong break through of resistance. If breakthrough occurs we will see some nice upside to $200-$215
Looks like double bottom could be forming...watch for strong bounce off bottom resistance line.
Support zone + Side of Bollinger bands + Hammer + Divergence + Nice discount
#SeattleGenetics is doing several impressive studies which helped stock price moved up.They stayed strong during the crash. It is doing well so far but it may stall for a while because of the coming resistances.
Hello Traders! It looks like $SGEN has made a local top and will be headed for consolidation. Not to worry, I believe continued upside potential is favored. My plan includes stacking buy orders at $90-$75 with stops at $70. Do your own DD, and good luck! Yo boy, Pic
$SGEN has been on a long-term bull run as we look at the weekly chart. Positive topline results signal that the bull run is set to continue and we expect $SGEN to keep racking up new 52-week highs. Seattle Genetics (NASDAQ:SGEN) is up in reaction to positive results from a Phase 2 clinical trial, HER2CLIMB, evaluating combination of tucatinib, Roche's Herceptin...
Earnings next week will spike Seattle Genetics, given its history for last several quarters of beating the estimate. If the whole market drops due to some international jitters like Crimea, etc, SGEN may fall a bit , but has solid support at 31.